ANAVEX LIFE SCIENCES CORP.
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $13.8M | $11.0M | $12.0M | — | — |
| Research and development | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M |
| Operating expenses | $51.4M | $52.9M | $55.8M | $51.0M | $42.0M |
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M |
| Pretax income | -$46.4M | -$43.0M | -$47.5M | -$47.6M | -$37.6M |
| Income tax expense | — | — | $7,000 | $358,000 | $268,000 |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M |
| Balance Sheet | |||||
| Cash and equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M |
| Stockholders' equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M |
| Stock-based compensation | $11.5M | $9.4M | $16.4M | $18.4M | $8.2M |
| Share repurchases | — | $11.3M | $27.9M | — | $24.1M |
Shares outstanding 92.7M · Free float 81.2%
Annual filing data through FY ended September 30, 2025; float as of July 12, 2026.